China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)
China
· Delayed Price · Currency is CNY 19.58
+0.17 (0.88%)
Apr 3, 2025, 3:00 PM CST
SHA:600062 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 1,628 | 1,333 | 1,180 | 935.69 | 1,005 | Upgrade
|
| Depreciation & Amortization | 755.54 | 640.81 | 561.85 | 467.29 | 374.36 | Upgrade
|
| Other Amortization | 5.94 | 14.65 | 3.95 | 3.26 | 3.67 | Upgrade
|
| Loss (Gain) From Sale of Assets | -46.84 | 0.06 | 2.27 | -1.03 | 22.52 | Upgrade
|
| Asset Writedown & Restructuring Costs | 110.52 | 79.53 | 8.43 | 56.92 | 43.42 | Upgrade
|
| Loss (Gain) From Sale of Investments | -153.5 | -26.35 | -22.22 | -62.47 | -31.84 | Upgrade
|
| Provision & Write-off of Bad Debts | -18.21 | 8.79 | 1.49 | 2.47 | 4.17 | Upgrade
|
| Other Operating Activities | 33.77 | 10.97 | 7.83 | 27.41 | -1.83 | Upgrade
|
| Change in Accounts Receivable | -443.3 | -488.67 | -232.69 | -130.71 | -216.17 | Upgrade
|
| Change in Inventory | 71.64 | 315.68 | -33.13 | -384.47 | -146.76 | Upgrade
|
| Change in Accounts Payable | -69.23 | -221.6 | -86.31 | 395.5 | 303.64 | Upgrade
|
| Change in Unearned Revenue | -21.64 | -18.83 | 44.81 | 52.9 | 5.87 | Upgrade
|
| Change in Other Net Operating Assets | 2.92 | 0.83 | 2.56 | 1.94 | -0.12 | Upgrade
|
| Operating Cash Flow | 1,825 | 1,631 | 1,416 | 1,341 | 1,360 | Upgrade
|
| Operating Cash Flow Growth | 11.92% | 15.15% | 5.61% | -1.41% | -5.53% | Upgrade
|
| Capital Expenditures | -637.5 | -604.47 | -526.6 | -491.67 | -348.09 | Upgrade
|
| Sale of Property, Plant & Equipment | 57.1 | 2.95 | 3.91 | 11.41 | 42.66 | Upgrade
|
| Cash Acquisitions | - | -130.18 | -409.22 | 13.65 | - | Upgrade
|
| Divestitures | - | - | - | 36.59 | - | Upgrade
|
| Investment in Securities | 241.42 | -37.01 | 1,507 | -177.36 | -157.23 | Upgrade
|
| Other Investing Activities | 1,321 | 82.29 | 17.28 | 37.57 | 44.68 | Upgrade
|
| Investing Cash Flow | 982.46 | -686.42 | 592.28 | -569.8 | -417.98 | Upgrade
|
| Long-Term Debt Issued | 1,148 | 15 | 1.45 | 4.75 | - | Upgrade
|
| Total Debt Issued | 1,148 | 15 | 1.45 | 4.75 | - | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -52.44 | -64.3 | Upgrade
|
| Long-Term Debt Repaid | -230.97 | -39.05 | -32.26 | -21.7 | - | Upgrade
|
| Total Debt Repaid | -230.97 | -39.05 | -32.26 | -74.14 | -64.3 | Upgrade
|
| Net Debt Issued (Repaid) | 917.3 | -24.05 | -30.81 | -69.4 | -64.3 | Upgrade
|
| Issuance of Common Stock | - | - | 144.72 | - | - | Upgrade
|
| Repurchase of Common Stock | - | -1.01 | -290.9 | - | - | Upgrade
|
| Common Dividends Paid | -1,485 | -305.89 | -801.76 | -302.59 | -319.33 | Upgrade
|
| Other Financing Activities | -2,617 | -28.73 | -312.42 | -6.63 | -2.55 | Upgrade
|
| Financing Cash Flow | -3,185 | -359.67 | -1,291 | -378.62 | -386.18 | Upgrade
|
| Foreign Exchange Rate Adjustments | 6.94 | 3.69 | 12.28 | 1.3 | -0.07 | Upgrade
|
| Net Cash Flow | -370.03 | 588.38 | 729.55 | 393.8 | 555.93 | Upgrade
|
| Free Cash Flow | 1,188 | 1,026 | 889.57 | 849.25 | 1,012 | Upgrade
|
| Free Cash Flow Growth | 15.72% | 15.37% | 4.75% | -16.09% | -15.53% | Upgrade
|
| Free Cash Flow Margin | 10.59% | 10.04% | 9.24% | 9.32% | 11.90% | Upgrade
|
| Free Cash Flow Per Share | 1.16 | 1.00 | 0.86 | 0.81 | 0.97 | Upgrade
|
| Cash Interest Paid | - | 1.35 | - | - | - | Upgrade
|
| Cash Income Tax Paid | - | 1,107 | 887.37 | 887.6 | 971.82 | Upgrade
|
| Levered Free Cash Flow | 1,765 | 1,496 | 202.43 | 309.37 | 952.36 | Upgrade
|
| Unlevered Free Cash Flow | 1,774 | 1,504 | 209.07 | 316.63 | 954.65 | Upgrade
|
| Change in Net Working Capital | -582.41 | -480.5 | 605.46 | 308.6 | -191.43 | Upgrade
|
Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.